Avicanna Inc's stock has had a mixed performance lately, reflecting ongoing developments in the health care sector.
This week, Avicanna Inc (AVCN.TO) saw a slight decline of 3.85% in its stock price, closing at C$0.13. However, over the past week, the stock gained 4.17%, indicating some volatility in its trading pattern. The company's latest news centers around the launch of the QUIX™ Rapid-Onset Medical Cannabis Portfolio, which aims to enhance its product offerings in the cannabis market.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Avicanna Inc
AVCN.TO
AVCN.TO
Avicanna Inc
WealthAwesomeMarket cap
$15.72M
52W high
$0.30
52W low
$0.10
1W change
-7.41%
Beta
0.33
Analyst Price Targets
Based on analyst covering AVCN
Wall Street analysts forecast AVCN stock price to rise 460.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.70
+460.0% Upside
Current Price
C$0.13
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on AVCN's historical volatility
30-Day Vol
70.3%
Annualized
90-Day Vol
65.4%
Annualized
Trend (90d)
-47.6%
Annualized drift
90d Mean
C$0.11
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.12 | C$0.09 – C$0.15 |
| 60 trading days | C$0.11 | C$0.08 – C$0.16 |
| 90 trading days | C$0.11 | C$0.07 – C$0.16 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should consider the implications of Avicanna's new product launch while monitoring its stock performance and technical indicators.
Avicanna's stock holds a market cap of C$15.72 million.
With a 52-week trading range between C$0.10 and C$0.31, the stock is currently trading at 14% of its range, highlighting its recent struggles.
Bull case
The launch of the QUIX™ product line could position Avicanna favorably in the competitive cannabis market, potentially leading to increased sales and market share.
Bear case
Despite the new product launch, the stock's performance remains volatile. Its fundamentals show ongoing challenges, including negative profit margins and a significant drop in year-to-date performance.
Recent Price Action
Advertisement
Avicanna Inc's stock closed at C$0.13, reflecting a decline of 3.85% in today's trading session. Over the past week, the stock has shown some resilience, gaining 4.17%. However, its year-to-date performance remains concerning, with a decline of 43.18%. These fluctuations can be attributed to the company's ongoing efforts to expand its product offerings amid a competitive cannabis market.
Company News: QUIX™ Launch
On July 16, 2026, Avicanna announced the launch of its QUIX™ Rapid-Onset Medical Cannabis Portfolio. This new product line aims to provide patients with quicker relief options, which could enhance the company's standing in the health care sector. The introduction of innovative products is crucial as the cannabis market evolves, and investor interest may rise as the company seeks to establish a stronger foothold in this space.
Technical Picture
From a technical standpoint, Avicanna's stock is currently trading at its 50-day moving average of C$0.13, slightly below this average by 0.9%. The 200-day moving average stands at C$0.19, indicating a significant 33.1% gap from the current price. The stock's 52-week range of C$0.10 to C$0.31 shows that it is currently trading at 14% of this range. With a beta of 0.33, the stock exhibits lower volatility compared to the broader market. Trading volume has been relatively low, with the latest volume at 121,192 shares, which is only 0.60 times the 20-day average volume of 202,628 shares, signaling cautious investor sentiment.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
